Woodline Partners LP Pliant Therapeutics, Inc. Transaction History

Woodline Partners LP

$11 Billion
Q3 2024

A detailed history of Woodline Partners LP transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 111,660 shares of PLRX stock, worth $1.51 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

111,660

Previous 103,623 7.76%

Holding current value

$1.51 Million

Previous $1.11 Million 12.4%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$10.52 - $14.35 $84,549 - $115,330	8,037 Added 7.76%	111,660 $1.25 Million
Q2 2024 Aug 14, 2024	BUY	$10.58 - $15.61 $36,818 - $54,322	3,480 Added 3.48%	103,623 $1.11 Million
Q1 2024 May 15, 2024	SELL	$14.14 - $19.59 $338,610 - $469,121	-23,947 Reduced 19.3%	100,143 $1.49 Million
Q4 2023 Feb 14, 2024	SELL	$12.85 - $19.15 $4.01 Million - $5.98 Million	-312,162 Reduced 71.56%	124,090 $2.25 Million
Q3 2023 Nov 14, 2023	BUY	$14.58 - $20.15 $2.61 Million - $3.6 Million	178,754 Added 69.42%	436,252 $7.56 Million
Q2 2023 Aug 14, 2023	BUY	$18.12 - $30.56 $4.67 Million - $7.87 Million	257,498 New	257,498 $4.67 Million
Q4 2021 Feb 14, 2022	SELL	$12.27 - $18.26 $2.21 Million - $3.29 Million	-179,993 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$16.48 - $28.98 $1.79 Million - $3.14 Million	108,330 Added 151.17%	179,993 $3.04 Million
Q2 2021 Aug 16, 2021	BUY	$28.05 - $37.69 $2.01 Million - $2.7 Million	71,663 New	71,663 $2.09 Million
Q4 2020 Feb 16, 2021	SELL	$19.89 - $32.99 $3.02 Million - $5.01 Million	-152,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$21.54 - $29.53 $3.27 Million - $4.49 Million	152,000 New	152,000 $3.44 Million

Others Institutions Holding PLRX

# of Institutions

168

Shares Held

63.2M

Call Options Held

245K

Put Options Held

373K

View Full List

About PLIANT THERAPEUTICS, INC.

Ticker PLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,682,000
Market Cap $657M
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...

More about PLRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.

Account

Woodline Partners LP Pliant Therapeutics, Inc. Transaction History